Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment

被引：0
|
作者：
Genovese, Mark C. [1 ]
van Hoogstraten, Hubert [2 ]
St John, Gregory [3 ]
Dong, Qunming [2 ]
Jose Gomez-Reino, Juan [4 ]
Maldonado-Cocco, Jose A. [5 ]
Carlos Salazar, Juan [6 ]
Huizinga, Tom W. J. [7 ]
Burmester, Gerd R. [8 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Sanofi Genzyme, Bridgewater, NJ USA
[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Complejo Hosp Univ Santiago de Compostela, Santiago, Spain
[5] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina
[6] Riesgo Fractura SA CAYRE, Bogota, Colombia
[7] Leiden Univ, Med Ctr, Leiden, Netherlands
[8] Charite Univ Med Berlin, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2509
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Roy Fleischmann
    [J]. Clinical Rheumatology, 2021, 40 : 4369 - 4372
  • [22] The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope
    Mercer, Louise
    Abhishek, Abhishek
    Kavirayani, Akhila
    Ahmed, Alison
    Davidson, Alan
    Foulkes, Amy
    Jones, Claire
    Nash, Clare
    Rose-Parfitt, Emily
    Dhillon, Emmandeep
    Zabate, Genevieve
    Twohig, Helen
    De Vere, Hope
    Scott, Jennifer
    Reynolds, John
    Holmes, Julia
    Hartley, Karen
    Warrier, Kishore
    Nowak, Kataryzna
    Parsons, Kate
    Bechman, Katie
    Bray, Lisa
    Adikari, Madura
    Wood, Natasha
    Faithfull, Nicola
    Gullick, Nicola
    Saha, Pratyasha
    Heaton, Rebecca
    Deepak, Samundeeswari
    Hider, Samantha
    Khalid, Sameena
    Said, Sanaa Suleiman
    Ryan, Sarah
    Kyle, Stuart
    Raghuvanshi, Subhra
    Tan, Su-Yin
    Shivamurthy, Vinay
    Galloway, James
    [J]. RHEUMATOLOGY ADVANCES IN PRACTICE, 2024, 8 (03)
  • [23] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [24] Predictors of disease flare following tapering of conventional synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis remission
    Sundlisaeter, N. P.
    Sexton, J.
    Aga, A.
    Uhlig, T.
    Solomon, D. H.
    Van der Heijde, D.
    Kvien, T. K.
    Haavardsholm, E. A.
    Lillegraven, S.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 : 10 - 11
  • [25] Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3476 - 3479
  • [26] Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
    Genovese, Mark C.
    van der Heijde, Desiree
    Lin, Yong
    St John, Gregory
    Wang, Sheldon
    van Hoogstraten, Hubert
    Jose Gomez-Reino, Juan
    Kivitz, Alan
    Antonio Maldonado-Cocco, Jose
    Seriolo, Bruno
    Stanislav, Marina
    Burmester, Gerd R.
    [J]. RMD OPEN, 2019, 5 (02):
  • [27] SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER (IR) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Dore, R. K.
    Antonova, J.
    Huang, H.
    Gorritz, M.
    Genovese, M. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S174 - S174
  • [28] Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study
    Howren, A.
    Rebic, N.
    Sayre, E. C.
    Tsao, N. W.
    Amiri, N.
    Baldwin, C.
    De Vera, M. A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (06) : 1080 - 1087
  • [29] Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Vascular Dementia in Patients with Spondyloarthritis: A Database Cohort Study
    Lee, Yu-Hao
    Huang, Shih-Wei
    Chen, Chih-Kuang
    Hong, Jia-Pei
    Chen, Yi-Wen
    Lin, Hui-Wen
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [30] Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
    Curtis, Jeffrey
    Lin, Yong
    Thangavelu, Karthinathan
    Stanislav, Marina
    St John, Gregory
    Gomez-Centeno, Antonio
    Selmi, Carlo
    Huizinga, Thomas
    Antonio Maldonado-Cocco, Jose
    Bukhari, Marwan
    Buttgereit, Frank
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345